Dade and Aventis strike cardiovascular marker deal
This article was originally published in Clinica
Executive Summary
In what could lead to new tests for cardiovascular disease, Dade Behring and Aventis Behring have formed a deal relating to what has been described as the first marker to link coagulation disorders and arterial disease.